Global HIV Antiretroviral Drug Market Research Report 2023
This report aims to provide a comprehensive presentation of the global market for HIV Antiretroviral Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding HIV Antiretroviral Drug.
The HIV Antiretroviral Drug market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global HIV Antiretroviral Drug market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the HIV Antiretroviral Drug companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of HIV Antiretroviral Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The HIV Antiretroviral Drug market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global HIV Antiretroviral Drug market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the HIV Antiretroviral Drug companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
- ViiV Healthcare(GlaxoSmithKline)
- Gilead Sciences
- AbbVie Inc.
- Merck & Co
- GSK
- Bristol-Myers Squibb Company
- Theratechnologies Inc.
- Roche Holding AG
- Teva Pharmaceuticals
- Pfizer
- Frontier Biotechnologies
- Shionogi
- Julphar Bangladesh
- Mylan Pharmaceuticals Inc.
- Genentech, Inc.
- Boehringer Ingelheim
- Cipla
- MSD
- Abbott
- Johnson & Johnson
- Biocon Limited
- Affine Formulations Limited
- IPCA Laboratories
- Natco Pharma
- Beacon Pharmaceuticals
- Nucleoside Reverse Transcriptase Inhibitors
- Non-Nucleoside Reverse Transcriptase Inhibitors
- Protease Inhibitors
- Fusion Inhibitors
- Others
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- North America
- United States
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Nordic Countries
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of HIV Antiretroviral Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 REPORT OVERVIEW
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global HIV Antiretroviral Drug Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Nucleoside Reverse Transcriptase Inhibitors
1.2.3 Non-Nucleoside Reverse Transcriptase Inhibitors
1.2.4 Protease Inhibitors
1.2.5 Fusion Inhibitors
1.2.6 Others
1.3 Market by Application
1.3.1 Global HIV Antiretroviral Drug Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global HIV Antiretroviral Drug Market Perspective (2018-2029)
2.2 HIV Antiretroviral Drug Growth Trends by Region
2.2.1 Global HIV Antiretroviral Drug Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 HIV Antiretroviral Drug Historic Market Size by Region (2018-2023)
2.2.3 HIV Antiretroviral Drug Forecasted Market Size by Region (2024-2029)
2.3 HIV Antiretroviral Drug Market Dynamics
2.3.1 HIV Antiretroviral Drug Industry Trends
2.3.2 HIV Antiretroviral Drug Market Drivers
2.3.3 HIV Antiretroviral Drug Market Challenges
2.3.4 HIV Antiretroviral Drug Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top HIV Antiretroviral Drug Players by Revenue
3.1.1 Global Top HIV Antiretroviral Drug Players by Revenue (2018-2023)
3.1.2 Global HIV Antiretroviral Drug Revenue Market Share by Players (2018-2023)
3.2 Global HIV Antiretroviral Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by HIV Antiretroviral Drug Revenue
3.4 Global HIV Antiretroviral Drug Market Concentration Ratio
3.4.1 Global HIV Antiretroviral Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by HIV Antiretroviral Drug Revenue in 2022
3.5 HIV Antiretroviral Drug Key Players Head office and Area Served
3.6 Key Players HIV Antiretroviral Drug Product Solution and Service
3.7 Date of Enter into HIV Antiretroviral Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 HIV ANTIRETROVIRAL DRUG BREAKDOWN DATA BY TYPE
4.1 Global HIV Antiretroviral Drug Historic Market Size by Type (2018-2023)
4.2 Global HIV Antiretroviral Drug Forecasted Market Size by Type (2024-2029)
5 HIV ANTIRETROVIRAL DRUG BREAKDOWN DATA BY APPLICATION
5.1 Global HIV Antiretroviral Drug Historic Market Size by Application (2018-2023)
5.2 Global HIV Antiretroviral Drug Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America HIV Antiretroviral Drug Market Size (2018-2029)
6.2 North America HIV Antiretroviral Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America HIV Antiretroviral Drug Market Size by Country (2018-2023)
6.4 North America HIV Antiretroviral Drug Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 EUROPE
7.1 Europe HIV Antiretroviral Drug Market Size (2018-2029)
7.2 Europe HIV Antiretroviral Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe HIV Antiretroviral Drug Market Size by Country (2018-2023)
7.4 Europe HIV Antiretroviral Drug Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 ASIA-PACIFIC
8.1 Asia-Pacific HIV Antiretroviral Drug Market Size (2018-2029)
8.2 Asia-Pacific HIV Antiretroviral Drug Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific HIV Antiretroviral Drug Market Size by Region (2018-2023)
8.4 Asia-Pacific HIV Antiretroviral Drug Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 LATIN AMERICA
9.1 Latin America HIV Antiretroviral Drug Market Size (2018-2029)
9.2 Latin America HIV Antiretroviral Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America HIV Antiretroviral Drug Market Size by Country (2018-2023)
9.4 Latin America HIV Antiretroviral Drug Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa HIV Antiretroviral Drug Market Size (2018-2029)
10.2 Middle East & Africa HIV Antiretroviral Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa HIV Antiretroviral Drug Market Size by Country (2018-2023)
10.4 Middle East & Africa HIV Antiretroviral Drug Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 KEY PLAYERS PROFILES
11.1 ViiV Healthcare(GlaxoSmithKline)
11.1.1 ViiV Healthcare(GlaxoSmithKline) Company Detail
11.1.2 ViiV Healthcare(GlaxoSmithKline) Business Overview
11.1.3 ViiV Healthcare(GlaxoSmithKline) HIV Antiretroviral Drug Introduction
11.1.4 ViiV Healthcare(GlaxoSmithKline) Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.1.5 ViiV Healthcare(GlaxoSmithKline) Recent Development
11.2 Gilead Sciences
11.2.1 Gilead Sciences Company Detail
11.2.2 Gilead Sciences Business Overview
11.2.3 Gilead Sciences HIV Antiretroviral Drug Introduction
11.2.4 Gilead Sciences Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.2.5 Gilead Sciences Recent Development
11.3 AbbVie Inc.
11.3.1 AbbVie Inc. Company Detail
11.3.2 AbbVie Inc. Business Overview
11.3.3 AbbVie Inc. HIV Antiretroviral Drug Introduction
11.3.4 AbbVie Inc. Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.3.5 AbbVie Inc. Recent Development
11.4 Merck & Co
11.4.1 Merck & Co Company Detail
11.4.2 Merck & Co Business Overview
11.4.3 Merck & Co HIV Antiretroviral Drug Introduction
11.4.4 Merck & Co Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.4.5 Merck & Co Recent Development
11.5 GSK
11.5.1 GSK Company Detail
11.5.2 GSK Business Overview
11.5.3 GSK HIV Antiretroviral Drug Introduction
11.5.4 GSK Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.5.5 GSK Recent Development
11.6 Bristol-Myers Squibb Company
11.6.1 Bristol-Myers Squibb Company Company Detail
11.6.2 Bristol-Myers Squibb Company Business Overview
11.6.3 Bristol-Myers Squibb Company HIV Antiretroviral Drug Introduction
11.6.4 Bristol-Myers Squibb Company Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.6.5 Bristol-Myers Squibb Company Recent Development
11.7 Theratechnologies Inc.
11.7.1 Theratechnologies Inc. Company Detail
11.7.2 Theratechnologies Inc. Business Overview
11.7.3 Theratechnologies Inc. HIV Antiretroviral Drug Introduction
11.7.4 Theratechnologies Inc. Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.7.5 Theratechnologies Inc. Recent Development
11.8 Roche Holding AG
11.8.1 Roche Holding AG Company Detail
11.8.2 Roche Holding AG Business Overview
11.8.3 Roche Holding AG HIV Antiretroviral Drug Introduction
11.8.4 Roche Holding AG Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.8.5 Roche Holding AG Recent Development
11.9 Teva Pharmaceuticals
11.9.1 Teva Pharmaceuticals Company Detail
11.9.2 Teva Pharmaceuticals Business Overview
11.9.3 Teva Pharmaceuticals HIV Antiretroviral Drug Introduction
11.9.4 Teva Pharmaceuticals Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.9.5 Teva Pharmaceuticals Recent Development
11.10 Pfizer
11.10.1 Pfizer Company Detail
11.10.2 Pfizer Business Overview
11.10.3 Pfizer HIV Antiretroviral Drug Introduction
11.10.4 Pfizer Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.10.5 Pfizer Recent Development
11.11 Frontier Biotechnologies
11.11.1 Frontier Biotechnologies Company Detail
11.11.2 Frontier Biotechnologies Business Overview
11.11.3 Frontier Biotechnologies HIV Antiretroviral Drug Introduction
11.11.4 Frontier Biotechnologies Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.11.5 Frontier Biotechnologies Recent Development
11.12 Shionogi
11.12.1 Shionogi Company Detail
11.12.2 Shionogi Business Overview
11.12.3 Shionogi HIV Antiretroviral Drug Introduction
11.12.4 Shionogi Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.12.5 Shionogi Recent Development
11.13 Julphar Bangladesh
11.13.1 Julphar Bangladesh Company Detail
11.13.2 Julphar Bangladesh Business Overview
11.13.3 Julphar Bangladesh HIV Antiretroviral Drug Introduction
11.13.4 Julphar Bangladesh Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.13.5 Julphar Bangladesh Recent Development
11.14 Mylan Pharmaceuticals Inc.
11.14.1 Mylan Pharmaceuticals Inc. Company Detail
11.14.2 Mylan Pharmaceuticals Inc. Business Overview
11.14.3 Mylan Pharmaceuticals Inc. HIV Antiretroviral Drug Introduction
11.14.4 Mylan Pharmaceuticals Inc. Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.14.5 Mylan Pharmaceuticals Inc. Recent Development
11.15 Genentech, Inc.
11.15.1 Genentech, Inc. Company Detail
11.15.2 Genentech, Inc. Business Overview
11.15.3 Genentech, Inc. HIV Antiretroviral Drug Introduction
11.15.4 Genentech, Inc. Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.15.5 Genentech, Inc. Recent Development
11.16 Boehringer Ingelheim
11.16.1 Boehringer Ingelheim Company Detail
11.16.2 Boehringer Ingelheim Business Overview
11.16.3 Boehringer Ingelheim HIV Antiretroviral Drug Introduction
11.16.4 Boehringer Ingelheim Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.16.5 Boehringer Ingelheim Recent Development
11.17 Cipla
11.17.1 Cipla Company Detail
11.17.2 Cipla Business Overview
11.17.3 Cipla HIV Antiretroviral Drug Introduction
11.17.4 Cipla Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.17.5 Cipla Recent Development
11.18 MSD
11.18.1 MSD Company Detail
11.18.2 MSD Business Overview
11.18.3 MSD HIV Antiretroviral Drug Introduction
11.18.4 MSD Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.18.5 MSD Recent Development
11.19 Abbott
11.19.1 Abbott Company Detail
11.19.2 Abbott Business Overview
11.19.3 Abbott HIV Antiretroviral Drug Introduction
11.19.4 Abbott Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.19.5 Abbott Recent Development
11.20 Johnson & Johnson
11.20.1 Johnson & Johnson Company Detail
11.20.2 Johnson & Johnson Business Overview
11.20.3 Johnson & Johnson HIV Antiretroviral Drug Introduction
11.20.4 Johnson & Johnson Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.20.5 Johnson & Johnson Recent Development
11.21 Biocon Limited
11.21.1 Biocon Limited Company Detail
11.21.2 Biocon Limited Business Overview
11.21.3 Biocon Limited HIV Antiretroviral Drug Introduction
11.21.4 Biocon Limited Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.21.5 Biocon Limited Recent Development
11.22 Affine Formulations Limited
11.22.1 Affine Formulations Limited Company Detail
11.22.2 Affine Formulations Limited Business Overview
11.22.3 Affine Formulations Limited HIV Antiretroviral Drug Introduction
11.22.4 Affine Formulations Limited Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.22.5 Affine Formulations Limited Recent Development
11.23 IPCA Laboratories
11.23.1 IPCA Laboratories Company Detail
11.23.2 IPCA Laboratories Business Overview
11.23.3 IPCA Laboratories HIV Antiretroviral Drug Introduction
11.23.4 IPCA Laboratories Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.23.5 IPCA Laboratories Recent Development
11.24 Natco Pharma
11.24.1 Natco Pharma Company Detail
11.24.2 Natco Pharma Business Overview
11.24.3 Natco Pharma HIV Antiretroviral Drug Introduction
11.24.4 Natco Pharma Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.24.5 Natco Pharma Recent Development
11.25 Beacon Pharmaceuticals
11.25.1 Beacon Pharmaceuticals Company Detail
11.25.2 Beacon Pharmaceuticals Business Overview
11.25.3 Beacon Pharmaceuticals HIV Antiretroviral Drug Introduction
11.25.4 Beacon Pharmaceuticals Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.25.5 Beacon Pharmaceuticals Recent Development
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global HIV Antiretroviral Drug Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Nucleoside Reverse Transcriptase Inhibitors
1.2.3 Non-Nucleoside Reverse Transcriptase Inhibitors
1.2.4 Protease Inhibitors
1.2.5 Fusion Inhibitors
1.2.6 Others
1.3 Market by Application
1.3.1 Global HIV Antiretroviral Drug Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global HIV Antiretroviral Drug Market Perspective (2018-2029)
2.2 HIV Antiretroviral Drug Growth Trends by Region
2.2.1 Global HIV Antiretroviral Drug Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 HIV Antiretroviral Drug Historic Market Size by Region (2018-2023)
2.2.3 HIV Antiretroviral Drug Forecasted Market Size by Region (2024-2029)
2.3 HIV Antiretroviral Drug Market Dynamics
2.3.1 HIV Antiretroviral Drug Industry Trends
2.3.2 HIV Antiretroviral Drug Market Drivers
2.3.3 HIV Antiretroviral Drug Market Challenges
2.3.4 HIV Antiretroviral Drug Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top HIV Antiretroviral Drug Players by Revenue
3.1.1 Global Top HIV Antiretroviral Drug Players by Revenue (2018-2023)
3.1.2 Global HIV Antiretroviral Drug Revenue Market Share by Players (2018-2023)
3.2 Global HIV Antiretroviral Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by HIV Antiretroviral Drug Revenue
3.4 Global HIV Antiretroviral Drug Market Concentration Ratio
3.4.1 Global HIV Antiretroviral Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by HIV Antiretroviral Drug Revenue in 2022
3.5 HIV Antiretroviral Drug Key Players Head office and Area Served
3.6 Key Players HIV Antiretroviral Drug Product Solution and Service
3.7 Date of Enter into HIV Antiretroviral Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 HIV ANTIRETROVIRAL DRUG BREAKDOWN DATA BY TYPE
4.1 Global HIV Antiretroviral Drug Historic Market Size by Type (2018-2023)
4.2 Global HIV Antiretroviral Drug Forecasted Market Size by Type (2024-2029)
5 HIV ANTIRETROVIRAL DRUG BREAKDOWN DATA BY APPLICATION
5.1 Global HIV Antiretroviral Drug Historic Market Size by Application (2018-2023)
5.2 Global HIV Antiretroviral Drug Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America HIV Antiretroviral Drug Market Size (2018-2029)
6.2 North America HIV Antiretroviral Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America HIV Antiretroviral Drug Market Size by Country (2018-2023)
6.4 North America HIV Antiretroviral Drug Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 EUROPE
7.1 Europe HIV Antiretroviral Drug Market Size (2018-2029)
7.2 Europe HIV Antiretroviral Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe HIV Antiretroviral Drug Market Size by Country (2018-2023)
7.4 Europe HIV Antiretroviral Drug Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 ASIA-PACIFIC
8.1 Asia-Pacific HIV Antiretroviral Drug Market Size (2018-2029)
8.2 Asia-Pacific HIV Antiretroviral Drug Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific HIV Antiretroviral Drug Market Size by Region (2018-2023)
8.4 Asia-Pacific HIV Antiretroviral Drug Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 LATIN AMERICA
9.1 Latin America HIV Antiretroviral Drug Market Size (2018-2029)
9.2 Latin America HIV Antiretroviral Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America HIV Antiretroviral Drug Market Size by Country (2018-2023)
9.4 Latin America HIV Antiretroviral Drug Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa HIV Antiretroviral Drug Market Size (2018-2029)
10.2 Middle East & Africa HIV Antiretroviral Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa HIV Antiretroviral Drug Market Size by Country (2018-2023)
10.4 Middle East & Africa HIV Antiretroviral Drug Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 KEY PLAYERS PROFILES
11.1 ViiV Healthcare(GlaxoSmithKline)
11.1.1 ViiV Healthcare(GlaxoSmithKline) Company Detail
11.1.2 ViiV Healthcare(GlaxoSmithKline) Business Overview
11.1.3 ViiV Healthcare(GlaxoSmithKline) HIV Antiretroviral Drug Introduction
11.1.4 ViiV Healthcare(GlaxoSmithKline) Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.1.5 ViiV Healthcare(GlaxoSmithKline) Recent Development
11.2 Gilead Sciences
11.2.1 Gilead Sciences Company Detail
11.2.2 Gilead Sciences Business Overview
11.2.3 Gilead Sciences HIV Antiretroviral Drug Introduction
11.2.4 Gilead Sciences Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.2.5 Gilead Sciences Recent Development
11.3 AbbVie Inc.
11.3.1 AbbVie Inc. Company Detail
11.3.2 AbbVie Inc. Business Overview
11.3.3 AbbVie Inc. HIV Antiretroviral Drug Introduction
11.3.4 AbbVie Inc. Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.3.5 AbbVie Inc. Recent Development
11.4 Merck & Co
11.4.1 Merck & Co Company Detail
11.4.2 Merck & Co Business Overview
11.4.3 Merck & Co HIV Antiretroviral Drug Introduction
11.4.4 Merck & Co Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.4.5 Merck & Co Recent Development
11.5 GSK
11.5.1 GSK Company Detail
11.5.2 GSK Business Overview
11.5.3 GSK HIV Antiretroviral Drug Introduction
11.5.4 GSK Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.5.5 GSK Recent Development
11.6 Bristol-Myers Squibb Company
11.6.1 Bristol-Myers Squibb Company Company Detail
11.6.2 Bristol-Myers Squibb Company Business Overview
11.6.3 Bristol-Myers Squibb Company HIV Antiretroviral Drug Introduction
11.6.4 Bristol-Myers Squibb Company Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.6.5 Bristol-Myers Squibb Company Recent Development
11.7 Theratechnologies Inc.
11.7.1 Theratechnologies Inc. Company Detail
11.7.2 Theratechnologies Inc. Business Overview
11.7.3 Theratechnologies Inc. HIV Antiretroviral Drug Introduction
11.7.4 Theratechnologies Inc. Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.7.5 Theratechnologies Inc. Recent Development
11.8 Roche Holding AG
11.8.1 Roche Holding AG Company Detail
11.8.2 Roche Holding AG Business Overview
11.8.3 Roche Holding AG HIV Antiretroviral Drug Introduction
11.8.4 Roche Holding AG Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.8.5 Roche Holding AG Recent Development
11.9 Teva Pharmaceuticals
11.9.1 Teva Pharmaceuticals Company Detail
11.9.2 Teva Pharmaceuticals Business Overview
11.9.3 Teva Pharmaceuticals HIV Antiretroviral Drug Introduction
11.9.4 Teva Pharmaceuticals Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.9.5 Teva Pharmaceuticals Recent Development
11.10 Pfizer
11.10.1 Pfizer Company Detail
11.10.2 Pfizer Business Overview
11.10.3 Pfizer HIV Antiretroviral Drug Introduction
11.10.4 Pfizer Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.10.5 Pfizer Recent Development
11.11 Frontier Biotechnologies
11.11.1 Frontier Biotechnologies Company Detail
11.11.2 Frontier Biotechnologies Business Overview
11.11.3 Frontier Biotechnologies HIV Antiretroviral Drug Introduction
11.11.4 Frontier Biotechnologies Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.11.5 Frontier Biotechnologies Recent Development
11.12 Shionogi
11.12.1 Shionogi Company Detail
11.12.2 Shionogi Business Overview
11.12.3 Shionogi HIV Antiretroviral Drug Introduction
11.12.4 Shionogi Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.12.5 Shionogi Recent Development
11.13 Julphar Bangladesh
11.13.1 Julphar Bangladesh Company Detail
11.13.2 Julphar Bangladesh Business Overview
11.13.3 Julphar Bangladesh HIV Antiretroviral Drug Introduction
11.13.4 Julphar Bangladesh Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.13.5 Julphar Bangladesh Recent Development
11.14 Mylan Pharmaceuticals Inc.
11.14.1 Mylan Pharmaceuticals Inc. Company Detail
11.14.2 Mylan Pharmaceuticals Inc. Business Overview
11.14.3 Mylan Pharmaceuticals Inc. HIV Antiretroviral Drug Introduction
11.14.4 Mylan Pharmaceuticals Inc. Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.14.5 Mylan Pharmaceuticals Inc. Recent Development
11.15 Genentech, Inc.
11.15.1 Genentech, Inc. Company Detail
11.15.2 Genentech, Inc. Business Overview
11.15.3 Genentech, Inc. HIV Antiretroviral Drug Introduction
11.15.4 Genentech, Inc. Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.15.5 Genentech, Inc. Recent Development
11.16 Boehringer Ingelheim
11.16.1 Boehringer Ingelheim Company Detail
11.16.2 Boehringer Ingelheim Business Overview
11.16.3 Boehringer Ingelheim HIV Antiretroviral Drug Introduction
11.16.4 Boehringer Ingelheim Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.16.5 Boehringer Ingelheim Recent Development
11.17 Cipla
11.17.1 Cipla Company Detail
11.17.2 Cipla Business Overview
11.17.3 Cipla HIV Antiretroviral Drug Introduction
11.17.4 Cipla Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.17.5 Cipla Recent Development
11.18 MSD
11.18.1 MSD Company Detail
11.18.2 MSD Business Overview
11.18.3 MSD HIV Antiretroviral Drug Introduction
11.18.4 MSD Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.18.5 MSD Recent Development
11.19 Abbott
11.19.1 Abbott Company Detail
11.19.2 Abbott Business Overview
11.19.3 Abbott HIV Antiretroviral Drug Introduction
11.19.4 Abbott Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.19.5 Abbott Recent Development
11.20 Johnson & Johnson
11.20.1 Johnson & Johnson Company Detail
11.20.2 Johnson & Johnson Business Overview
11.20.3 Johnson & Johnson HIV Antiretroviral Drug Introduction
11.20.4 Johnson & Johnson Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.20.5 Johnson & Johnson Recent Development
11.21 Biocon Limited
11.21.1 Biocon Limited Company Detail
11.21.2 Biocon Limited Business Overview
11.21.3 Biocon Limited HIV Antiretroviral Drug Introduction
11.21.4 Biocon Limited Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.21.5 Biocon Limited Recent Development
11.22 Affine Formulations Limited
11.22.1 Affine Formulations Limited Company Detail
11.22.2 Affine Formulations Limited Business Overview
11.22.3 Affine Formulations Limited HIV Antiretroviral Drug Introduction
11.22.4 Affine Formulations Limited Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.22.5 Affine Formulations Limited Recent Development
11.23 IPCA Laboratories
11.23.1 IPCA Laboratories Company Detail
11.23.2 IPCA Laboratories Business Overview
11.23.3 IPCA Laboratories HIV Antiretroviral Drug Introduction
11.23.4 IPCA Laboratories Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.23.5 IPCA Laboratories Recent Development
11.24 Natco Pharma
11.24.1 Natco Pharma Company Detail
11.24.2 Natco Pharma Business Overview
11.24.3 Natco Pharma HIV Antiretroviral Drug Introduction
11.24.4 Natco Pharma Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.24.5 Natco Pharma Recent Development
11.25 Beacon Pharmaceuticals
11.25.1 Beacon Pharmaceuticals Company Detail
11.25.2 Beacon Pharmaceuticals Business Overview
11.25.3 Beacon Pharmaceuticals HIV Antiretroviral Drug Introduction
11.25.4 Beacon Pharmaceuticals Revenue in HIV Antiretroviral Drug Business (2018-2023)
11.25.5 Beacon Pharmaceuticals Recent Development
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
LIST OF TABLES
Table 1. Global HIV Antiretroviral Drug Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Nucleoside Reverse Transcriptase Inhibitors
Table 3. Key Players of Non-Nucleoside Reverse Transcriptase Inhibitors
Table 4. Key Players of Protease Inhibitors
Table 5. Key Players of Fusion Inhibitors
Table 6. Key Players of Others
Table 7. Global HIV Antiretroviral Drug Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 8. Global HIV Antiretroviral Drug Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 9. Global HIV Antiretroviral Drug Market Size by Region (2018-2023) & (US$ Million)
Table 10. Global HIV Antiretroviral Drug Market Share by Region (2018-2023)
Table 11. Global HIV Antiretroviral Drug Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 12. Global HIV Antiretroviral Drug Market Share by Region (2024-2029)
Table 13. HIV Antiretroviral Drug Market Trends
Table 14. HIV Antiretroviral Drug Market Drivers
Table 15. HIV Antiretroviral Drug Market Challenges
Table 16. HIV Antiretroviral Drug Market Restraints
Table 17. Global HIV Antiretroviral Drug Revenue by Players (2018-2023) & (US$ Million)
Table 18. Global HIV Antiretroviral Drug Market Share by Players (2018-2023)
Table 19. Global Top HIV Antiretroviral Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in HIV Antiretroviral Drug as of 2022)
Table 20. Ranking of Global Top HIV Antiretroviral Drug Companies by Revenue (US$ Million) in 2022
Table 21. Global 5 Largest Players Market Share by HIV Antiretroviral Drug Revenue (CR5 and HHI) & (2018-2023)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players HIV Antiretroviral Drug Product Solution and Service
Table 24. Date of Enter into HIV Antiretroviral Drug Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global HIV Antiretroviral Drug Market Size by Type (2018-2023) & (US$ Million)
Table 27. Global HIV Antiretroviral Drug Revenue Market Share by Type (2018-2023)
Table 28. Global HIV Antiretroviral Drug Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 29. Global HIV Antiretroviral Drug Revenue Market Share by Type (2024-2029)
Table 30. Global HIV Antiretroviral Drug Market Size by Application (2018-2023) & (US$ Million)
Table 31. Global HIV Antiretroviral Drug Revenue Market Share by Application (2018-2023)
Table 32. Global HIV Antiretroviral Drug Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 33. Global HIV Antiretroviral Drug Revenue Market Share by Application (2024-2029)
Table 34. North America HIV Antiretroviral Drug Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 35. North America HIV Antiretroviral Drug Market Size by Country (2018-2023) & (US$ Million)
Table 36. North America HIV Antiretroviral Drug Market Size by Country (2024-2029) & (US$ Million)
Table 37. Europe HIV Antiretroviral Drug Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 38. Europe HIV Antiretroviral Drug Market Size by Country (2018-2023) & (US$ Million)
Table 39. Europe HIV Antiretroviral Drug Market Size by Country (2024-2029) & (US$ Million)
Table 40. Asia-Pacific HIV Antiretroviral Drug Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 41. Asia-Pacific HIV Antiretroviral Drug Market Size by Region (2018-2023) & (US$ Million)
Table 42. Asia-Pacific HIV Antiretroviral Drug Market Size by Region (2024-2029) & (US$ Million)
Table 43. Latin America HIV Antiretroviral Drug Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 44. Latin America HIV Antiretroviral Drug Market Size by Country (2018-2023) & (US$ Million)
Table 45. Latin America HIV Antiretroviral Drug Market Size by Country (2024-2029) & (US$ Million)
Table 46. Middle East & Africa HIV Antiretroviral Drug Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 47. Middle East & Africa HIV Antiretroviral Drug Market Size by Country (2018-2023) & (US$ Million)
Table 48. Middle East & Africa HIV Antiretroviral Drug Market Size by Country (2024-2029) & (US$ Million)
Table 49. ViiV Healthcare(GlaxoSmithKline) Company Detail
Table 50. ViiV Healthcare(GlaxoSmithKline) Business Overview
Table 51. ViiV Healthcare(GlaxoSmithKline) HIV Antiretroviral Drug Product
Table 52. ViiV Healthcare(GlaxoSmithKline) Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 53. ViiV Healthcare(GlaxoSmithKline) Recent Development
Table 54. Gilead Sciences Company Detail
Table 55. Gilead Sciences Business Overview
Table 56. Gilead Sciences HIV Antiretroviral Drug Product
Table 57. Gilead Sciences Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 58. Gilead Sciences Recent Development
Table 59. AbbVie Inc. Company Detail
Table 60. AbbVie Inc. Business Overview
Table 61. AbbVie Inc. HIV Antiretroviral Drug Product
Table 62. AbbVie Inc. Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 63. AbbVie Inc. Recent Development
Table 64. Merck & Co Company Detail
Table 65. Merck & Co Business Overview
Table 66. Merck & Co HIV Antiretroviral Drug Product
Table 67. Merck & Co Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 68. Merck & Co Recent Development
Table 69. GSK Company Detail
Table 70. GSK Business Overview
Table 71. GSK HIV Antiretroviral Drug Product
Table 72. GSK Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 73. GSK Recent Development
Table 74. Bristol-Myers Squibb Company Company Detail
Table 75. Bristol-Myers Squibb Company Business Overview
Table 76. Bristol-Myers Squibb Company HIV Antiretroviral Drug Product
Table 77. Bristol-Myers Squibb Company Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 78. Bristol-Myers Squibb Company Recent Development
Table 79. Theratechnologies Inc. Company Detail
Table 80. Theratechnologies Inc. Business Overview
Table 81. Theratechnologies Inc. HIV Antiretroviral Drug Product
Table 82. Theratechnologies Inc. Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 83. Theratechnologies Inc. Recent Development
Table 84. Roche Holding AG Company Detail
Table 85. Roche Holding AG Business Overview
Table 86. Roche Holding AG HIV Antiretroviral Drug Product
Table 87. Roche Holding AG Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 88. Roche Holding AG Recent Development
Table 89. Teva Pharmaceuticals Company Detail
Table 90. Teva Pharmaceuticals Business Overview
Table 91. Teva Pharmaceuticals HIV Antiretroviral Drug Product
Table 92. Teva Pharmaceuticals Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 93. Teva Pharmaceuticals Recent Development
Table 94. Pfizer Company Detail
Table 95. Pfizer Business Overview
Table 96. Pfizer HIV Antiretroviral Drug Product
Table 97. Pfizer Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 98. Pfizer Recent Development
Table 99. Frontier Biotechnologies Company Detail
Table 100. Frontier Biotechnologies Business Overview
Table 101. Frontier Biotechnologies HIV Antiretroviral Drug Product
Table 102. Frontier Biotechnologies Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 103. Frontier Biotechnologies Recent Development
Table 104. Shionogi Company Detail
Table 105. Shionogi Business Overview
Table 106. Shionogi HIV Antiretroviral Drug Product
Table 107. Shionogi Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 108. Shionogi Recent Development
Table 109. Julphar Bangladesh Company Detail
Table 110. Julphar Bangladesh Business Overview
Table 111. Julphar Bangladesh HIV Antiretroviral Drug Product
Table 112. Julphar Bangladesh Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 113. Julphar Bangladesh Recent Development
Table 114. Mylan Pharmaceuticals Inc. Company Detail
Table 115. Mylan Pharmaceuticals Inc. Business Overview
Table 116. Mylan Pharmaceuticals Inc. HIV Antiretroviral Drug Product
Table 117. Mylan Pharmaceuticals Inc. Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 118. Mylan Pharmaceuticals Inc. Recent Development
Table 119. Genentech, Inc. Company Detail
Table 120. Genentech, Inc. Business Overview
Table 121. Genentech, Inc. HIV Antiretroviral Drug Product
Table 122. Genentech, Inc. Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 123. Genentech, Inc. Recent Development
Table 124. Boehringer Ingelheim Company Detail
Table 125. Boehringer Ingelheim Business Overview
Table 126. Boehringer Ingelheim HIV Antiretroviral Drug Product
Table 127. Boehringer Ingelheim Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 128. Boehringer Ingelheim Recent Development
Table 129. Cipla Company Detail
Table 130. Cipla Business Overview
Table 131. Cipla HIV Antiretroviral Drug Product
Table 132. Cipla Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 133. Cipla Recent Development
Table 134. MSD Company Detail
Table 135. MSD Business Overview
Table 136. MSD HIV Antiretroviral Drug Product
Table 137. MSD Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 138. MSD Recent Development
Table 139. Abbott Company Detail
Table 140. Abbott Business Overview
Table 141. Abbott HIV Antiretroviral Drug Product
Table 142. Abbott Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 143. Abbott Recent Development
Table 144. Johnson & Johnson Company Detail
Table 145. Johnson & Johnson Business Overview
Table 146. Johnson & Johnson HIV Antiretroviral Drug Product
Table 147. Johnson & Johnson Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 148. Johnson & Johnson Recent Development
Table 149. Biocon Limited Company Detail
Table 150. Biocon Limited Business Overview
Table 151. Biocon Limited HIV Antiretroviral Drug Product
Table 152. Biocon Limited Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 153. Biocon Limited Recent Development
Table 154. Affine Formulations Limited Company Detail
Table 155. Affine Formulations Limited Business Overview
Table 156. Affine Formulations Limited HIV Antiretroviral Drug Product
Table 157. Affine Formulations Limited Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 158. Affine Formulations Limited Recent Development
Table 159. IPCA Laboratories Company Detail
Table 160. IPCA Laboratories Business Overview
Table 161. IPCA Laboratories HIV Antiretroviral Drug Product
Table 162. IPCA Laboratories Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 163. IPCA Laboratories Recent Development
Table 164. Natco Pharma Company Detail
Table 165. Natco Pharma Business Overview
Table 166. Natco Pharma HIV Antiretroviral Drug Product
Table 167. Natco Pharma Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 168. Natco Pharma Recent Development
Table 169. Beacon Pharmaceuticals Company Detail
Table 170. Beacon Pharmaceuticals Business Overview
Table 171. Beacon Pharmaceuticals HIV Antiretroviral Drug Product
Table 172. Beacon Pharmaceuticals Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 173. Beacon Pharmaceuticals Recent Development
Table 174. Research Programs/Design for This Report
Table 175. Key Data Information from Secondary Sources
Table 176. Key Data Information from Primary Sources
Table 1. Global HIV Antiretroviral Drug Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Nucleoside Reverse Transcriptase Inhibitors
Table 3. Key Players of Non-Nucleoside Reverse Transcriptase Inhibitors
Table 4. Key Players of Protease Inhibitors
Table 5. Key Players of Fusion Inhibitors
Table 6. Key Players of Others
Table 7. Global HIV Antiretroviral Drug Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 8. Global HIV Antiretroviral Drug Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 9. Global HIV Antiretroviral Drug Market Size by Region (2018-2023) & (US$ Million)
Table 10. Global HIV Antiretroviral Drug Market Share by Region (2018-2023)
Table 11. Global HIV Antiretroviral Drug Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 12. Global HIV Antiretroviral Drug Market Share by Region (2024-2029)
Table 13. HIV Antiretroviral Drug Market Trends
Table 14. HIV Antiretroviral Drug Market Drivers
Table 15. HIV Antiretroviral Drug Market Challenges
Table 16. HIV Antiretroviral Drug Market Restraints
Table 17. Global HIV Antiretroviral Drug Revenue by Players (2018-2023) & (US$ Million)
Table 18. Global HIV Antiretroviral Drug Market Share by Players (2018-2023)
Table 19. Global Top HIV Antiretroviral Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in HIV Antiretroviral Drug as of 2022)
Table 20. Ranking of Global Top HIV Antiretroviral Drug Companies by Revenue (US$ Million) in 2022
Table 21. Global 5 Largest Players Market Share by HIV Antiretroviral Drug Revenue (CR5 and HHI) & (2018-2023)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players HIV Antiretroviral Drug Product Solution and Service
Table 24. Date of Enter into HIV Antiretroviral Drug Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global HIV Antiretroviral Drug Market Size by Type (2018-2023) & (US$ Million)
Table 27. Global HIV Antiretroviral Drug Revenue Market Share by Type (2018-2023)
Table 28. Global HIV Antiretroviral Drug Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 29. Global HIV Antiretroviral Drug Revenue Market Share by Type (2024-2029)
Table 30. Global HIV Antiretroviral Drug Market Size by Application (2018-2023) & (US$ Million)
Table 31. Global HIV Antiretroviral Drug Revenue Market Share by Application (2018-2023)
Table 32. Global HIV Antiretroviral Drug Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 33. Global HIV Antiretroviral Drug Revenue Market Share by Application (2024-2029)
Table 34. North America HIV Antiretroviral Drug Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 35. North America HIV Antiretroviral Drug Market Size by Country (2018-2023) & (US$ Million)
Table 36. North America HIV Antiretroviral Drug Market Size by Country (2024-2029) & (US$ Million)
Table 37. Europe HIV Antiretroviral Drug Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 38. Europe HIV Antiretroviral Drug Market Size by Country (2018-2023) & (US$ Million)
Table 39. Europe HIV Antiretroviral Drug Market Size by Country (2024-2029) & (US$ Million)
Table 40. Asia-Pacific HIV Antiretroviral Drug Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 41. Asia-Pacific HIV Antiretroviral Drug Market Size by Region (2018-2023) & (US$ Million)
Table 42. Asia-Pacific HIV Antiretroviral Drug Market Size by Region (2024-2029) & (US$ Million)
Table 43. Latin America HIV Antiretroviral Drug Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 44. Latin America HIV Antiretroviral Drug Market Size by Country (2018-2023) & (US$ Million)
Table 45. Latin America HIV Antiretroviral Drug Market Size by Country (2024-2029) & (US$ Million)
Table 46. Middle East & Africa HIV Antiretroviral Drug Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 47. Middle East & Africa HIV Antiretroviral Drug Market Size by Country (2018-2023) & (US$ Million)
Table 48. Middle East & Africa HIV Antiretroviral Drug Market Size by Country (2024-2029) & (US$ Million)
Table 49. ViiV Healthcare(GlaxoSmithKline) Company Detail
Table 50. ViiV Healthcare(GlaxoSmithKline) Business Overview
Table 51. ViiV Healthcare(GlaxoSmithKline) HIV Antiretroviral Drug Product
Table 52. ViiV Healthcare(GlaxoSmithKline) Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 53. ViiV Healthcare(GlaxoSmithKline) Recent Development
Table 54. Gilead Sciences Company Detail
Table 55. Gilead Sciences Business Overview
Table 56. Gilead Sciences HIV Antiretroviral Drug Product
Table 57. Gilead Sciences Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 58. Gilead Sciences Recent Development
Table 59. AbbVie Inc. Company Detail
Table 60. AbbVie Inc. Business Overview
Table 61. AbbVie Inc. HIV Antiretroviral Drug Product
Table 62. AbbVie Inc. Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 63. AbbVie Inc. Recent Development
Table 64. Merck & Co Company Detail
Table 65. Merck & Co Business Overview
Table 66. Merck & Co HIV Antiretroviral Drug Product
Table 67. Merck & Co Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 68. Merck & Co Recent Development
Table 69. GSK Company Detail
Table 70. GSK Business Overview
Table 71. GSK HIV Antiretroviral Drug Product
Table 72. GSK Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 73. GSK Recent Development
Table 74. Bristol-Myers Squibb Company Company Detail
Table 75. Bristol-Myers Squibb Company Business Overview
Table 76. Bristol-Myers Squibb Company HIV Antiretroviral Drug Product
Table 77. Bristol-Myers Squibb Company Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 78. Bristol-Myers Squibb Company Recent Development
Table 79. Theratechnologies Inc. Company Detail
Table 80. Theratechnologies Inc. Business Overview
Table 81. Theratechnologies Inc. HIV Antiretroviral Drug Product
Table 82. Theratechnologies Inc. Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 83. Theratechnologies Inc. Recent Development
Table 84. Roche Holding AG Company Detail
Table 85. Roche Holding AG Business Overview
Table 86. Roche Holding AG HIV Antiretroviral Drug Product
Table 87. Roche Holding AG Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 88. Roche Holding AG Recent Development
Table 89. Teva Pharmaceuticals Company Detail
Table 90. Teva Pharmaceuticals Business Overview
Table 91. Teva Pharmaceuticals HIV Antiretroviral Drug Product
Table 92. Teva Pharmaceuticals Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 93. Teva Pharmaceuticals Recent Development
Table 94. Pfizer Company Detail
Table 95. Pfizer Business Overview
Table 96. Pfizer HIV Antiretroviral Drug Product
Table 97. Pfizer Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 98. Pfizer Recent Development
Table 99. Frontier Biotechnologies Company Detail
Table 100. Frontier Biotechnologies Business Overview
Table 101. Frontier Biotechnologies HIV Antiretroviral Drug Product
Table 102. Frontier Biotechnologies Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 103. Frontier Biotechnologies Recent Development
Table 104. Shionogi Company Detail
Table 105. Shionogi Business Overview
Table 106. Shionogi HIV Antiretroviral Drug Product
Table 107. Shionogi Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 108. Shionogi Recent Development
Table 109. Julphar Bangladesh Company Detail
Table 110. Julphar Bangladesh Business Overview
Table 111. Julphar Bangladesh HIV Antiretroviral Drug Product
Table 112. Julphar Bangladesh Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 113. Julphar Bangladesh Recent Development
Table 114. Mylan Pharmaceuticals Inc. Company Detail
Table 115. Mylan Pharmaceuticals Inc. Business Overview
Table 116. Mylan Pharmaceuticals Inc. HIV Antiretroviral Drug Product
Table 117. Mylan Pharmaceuticals Inc. Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 118. Mylan Pharmaceuticals Inc. Recent Development
Table 119. Genentech, Inc. Company Detail
Table 120. Genentech, Inc. Business Overview
Table 121. Genentech, Inc. HIV Antiretroviral Drug Product
Table 122. Genentech, Inc. Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 123. Genentech, Inc. Recent Development
Table 124. Boehringer Ingelheim Company Detail
Table 125. Boehringer Ingelheim Business Overview
Table 126. Boehringer Ingelheim HIV Antiretroviral Drug Product
Table 127. Boehringer Ingelheim Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 128. Boehringer Ingelheim Recent Development
Table 129. Cipla Company Detail
Table 130. Cipla Business Overview
Table 131. Cipla HIV Antiretroviral Drug Product
Table 132. Cipla Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 133. Cipla Recent Development
Table 134. MSD Company Detail
Table 135. MSD Business Overview
Table 136. MSD HIV Antiretroviral Drug Product
Table 137. MSD Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 138. MSD Recent Development
Table 139. Abbott Company Detail
Table 140. Abbott Business Overview
Table 141. Abbott HIV Antiretroviral Drug Product
Table 142. Abbott Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 143. Abbott Recent Development
Table 144. Johnson & Johnson Company Detail
Table 145. Johnson & Johnson Business Overview
Table 146. Johnson & Johnson HIV Antiretroviral Drug Product
Table 147. Johnson & Johnson Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 148. Johnson & Johnson Recent Development
Table 149. Biocon Limited Company Detail
Table 150. Biocon Limited Business Overview
Table 151. Biocon Limited HIV Antiretroviral Drug Product
Table 152. Biocon Limited Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 153. Biocon Limited Recent Development
Table 154. Affine Formulations Limited Company Detail
Table 155. Affine Formulations Limited Business Overview
Table 156. Affine Formulations Limited HIV Antiretroviral Drug Product
Table 157. Affine Formulations Limited Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 158. Affine Formulations Limited Recent Development
Table 159. IPCA Laboratories Company Detail
Table 160. IPCA Laboratories Business Overview
Table 161. IPCA Laboratories HIV Antiretroviral Drug Product
Table 162. IPCA Laboratories Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 163. IPCA Laboratories Recent Development
Table 164. Natco Pharma Company Detail
Table 165. Natco Pharma Business Overview
Table 166. Natco Pharma HIV Antiretroviral Drug Product
Table 167. Natco Pharma Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 168. Natco Pharma Recent Development
Table 169. Beacon Pharmaceuticals Company Detail
Table 170. Beacon Pharmaceuticals Business Overview
Table 171. Beacon Pharmaceuticals HIV Antiretroviral Drug Product
Table 172. Beacon Pharmaceuticals Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US$ Million)
Table 173. Beacon Pharmaceuticals Recent Development
Table 174. Research Programs/Design for This Report
Table 175. Key Data Information from Secondary Sources
Table 176. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Global HIV Antiretroviral Drug Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global HIV Antiretroviral Drug Market Share by Type: 2022 VS 2029
Figure 3. Nucleoside Reverse Transcriptase Inhibitors Features
Figure 4. Non-Nucleoside Reverse Transcriptase Inhibitors Features
Figure 5. Protease Inhibitors Features
Figure 6. Fusion Inhibitors Features
Figure 7. Others Features
Figure 8. Global HIV Antiretroviral Drug Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 9. Global HIV Antiretroviral Drug Market Share by Application: 2022 VS 2029
Figure 10. Hospital Pharmacies Case Studies
Figure 11. Retail Pharmacies Case Studies
Figure 12. Online Pharmacies Case Studies
Figure 13. HIV Antiretroviral Drug Report Years Considered
Figure 14. Global HIV Antiretroviral Drug Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 15. Global HIV Antiretroviral Drug Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 16. Global HIV Antiretroviral Drug Market Share by Region: 2022 VS 2029
Figure 17. Global HIV Antiretroviral Drug Market Share by Players in 2022
Figure 18. Global Top HIV Antiretroviral Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in HIV Antiretroviral Drug as of 2022)
Figure 19. The Top 10 and 5 Players Market Share by HIV Antiretroviral Drug Revenue in 2022
Figure 20. North America HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. North America HIV Antiretroviral Drug Market Share by Country (2018-2029)
Figure 22. United States HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Canada HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Europe HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Europe HIV Antiretroviral Drug Market Share by Country (2018-2029)
Figure 26. Germany HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. France HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. U.K. HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Italy HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Russia HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Nordic Countries HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Asia-Pacific HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Asia-Pacific HIV Antiretroviral Drug Market Share by Region (2018-2029)
Figure 34. China HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Japan HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. South Korea HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Southeast Asia HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. India HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Australia HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Latin America HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Latin America HIV Antiretroviral Drug Market Share by Country (2018-2029)
Figure 42. Mexico HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Brazil HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Middle East & Africa HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Middle East & Africa HIV Antiretroviral Drug Market Share by Country (2018-2029)
Figure 46. Turkey HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Saudi Arabia HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. ViiV Healthcare(GlaxoSmithKline) Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 49. Gilead Sciences Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 50. AbbVie Inc. Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 51. Merck & Co Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 52. GSK Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 53. Bristol-Myers Squibb Company Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 54. Theratechnologies Inc. Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 55. Roche Holding AG Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 56. Teva Pharmaceuticals Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 57. Pfizer Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 58. Frontier Biotechnologies Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 59. Shionogi Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 60. Julphar Bangladesh Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 61. Mylan Pharmaceuticals Inc. Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 62. Genentech, Inc. Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 63. Boehringer Ingelheim Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 64. Cipla Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 65. MSD Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 66. Abbott Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 67. Johnson & Johnson Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 68. Biocon Limited Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 69. Affine Formulations Limited Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 70. IPCA Laboratories Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 71. Natco Pharma Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 72. Beacon Pharmaceuticals Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed
Figure 1. Global HIV Antiretroviral Drug Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global HIV Antiretroviral Drug Market Share by Type: 2022 VS 2029
Figure 3. Nucleoside Reverse Transcriptase Inhibitors Features
Figure 4. Non-Nucleoside Reverse Transcriptase Inhibitors Features
Figure 5. Protease Inhibitors Features
Figure 6. Fusion Inhibitors Features
Figure 7. Others Features
Figure 8. Global HIV Antiretroviral Drug Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 9. Global HIV Antiretroviral Drug Market Share by Application: 2022 VS 2029
Figure 10. Hospital Pharmacies Case Studies
Figure 11. Retail Pharmacies Case Studies
Figure 12. Online Pharmacies Case Studies
Figure 13. HIV Antiretroviral Drug Report Years Considered
Figure 14. Global HIV Antiretroviral Drug Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 15. Global HIV Antiretroviral Drug Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 16. Global HIV Antiretroviral Drug Market Share by Region: 2022 VS 2029
Figure 17. Global HIV Antiretroviral Drug Market Share by Players in 2022
Figure 18. Global Top HIV Antiretroviral Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in HIV Antiretroviral Drug as of 2022)
Figure 19. The Top 10 and 5 Players Market Share by HIV Antiretroviral Drug Revenue in 2022
Figure 20. North America HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. North America HIV Antiretroviral Drug Market Share by Country (2018-2029)
Figure 22. United States HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Canada HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Europe HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Europe HIV Antiretroviral Drug Market Share by Country (2018-2029)
Figure 26. Germany HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. France HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. U.K. HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Italy HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Russia HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Nordic Countries HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Asia-Pacific HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Asia-Pacific HIV Antiretroviral Drug Market Share by Region (2018-2029)
Figure 34. China HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Japan HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. South Korea HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Southeast Asia HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. India HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Australia HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Latin America HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Latin America HIV Antiretroviral Drug Market Share by Country (2018-2029)
Figure 42. Mexico HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Brazil HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Middle East & Africa HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Middle East & Africa HIV Antiretroviral Drug Market Share by Country (2018-2029)
Figure 46. Turkey HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Saudi Arabia HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. ViiV Healthcare(GlaxoSmithKline) Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 49. Gilead Sciences Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 50. AbbVie Inc. Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 51. Merck & Co Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 52. GSK Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 53. Bristol-Myers Squibb Company Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 54. Theratechnologies Inc. Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 55. Roche Holding AG Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 56. Teva Pharmaceuticals Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 57. Pfizer Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 58. Frontier Biotechnologies Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 59. Shionogi Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 60. Julphar Bangladesh Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 61. Mylan Pharmaceuticals Inc. Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 62. Genentech, Inc. Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 63. Boehringer Ingelheim Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 64. Cipla Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 65. MSD Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 66. Abbott Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 67. Johnson & Johnson Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 68. Biocon Limited Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 69. Affine Formulations Limited Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 70. IPCA Laboratories Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 71. Natco Pharma Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 72. Beacon Pharmaceuticals Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed
